| Customization: | Available |
|---|---|
| CAS No.: | 147127-20-6 |
| Formula: | C9h14n5o4p |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Tenofovir |
| Apperence | White Crystalline Powder |
| CAS | 147127-20-6 |
| MF | C9H14N5O4P |
| MW | 287.21 |
HIV Treatment:
In the GS-96-901 trial, Tenofovir-based ART demonstrated 85% viral suppression (HIV RNA <50 copies/mL) at 48 weeks in treatment-naïve patients.Long-term studies show durable efficacy with a low incidence of resistance (≤2% over 5 years), attributed to its high genetic barrier.Chronic Hepatitis B:
The GS-98-902 trial reported 76% of patients achieving HBV DNA <400 copies/mL after 48 weeks of Tenofovir monotherapy.Histological improvement (reduced liver fibrosis) was observed in 72% of patients after 5 years of treatment.PrEP for HIV Prevention:
The iPrEx trial demonstrated a 44-75% reduction in HIV acquisition risk among high-risk populations using TDF/FTC PrEP, depending on adherence.
){kind=link}